

CHARITÉ/BIH-PARTNER WANTED!
More information [here](#)



Triox Nano

Short profile

Triox Nano Ltd

| | |
|-------------------------|--------------------------------|
| Medical field | Infectious Diseases / COVID 19 |
| Product (name and type) | TXN-C19, Nanotechnology |
| Growth stage | Proof of Concept |
| Founders | Roy Farfara (Founder, CTO) |

Description of product:

A mouthwash or nasal spray/inhalation based on uniquely designed nanoparticles coated with specifically programmed binding agents to the SARS-CoV-2 S protein RBD region in a higher predicted affinity, compared to its original target the human ACE2 receptor. The product is expected to form large viral aggregates, which will not be able to penetrate the host cell, and thus acts as a treatment.

Project goal:

Facilitating safe and rapid clearance of the virus from the patient's URT and lungs will lead to shorten disease time and a better outcome. The Product can provide a treatment option in COVID-19 or serve as preventive strategy / as post-exposure prophylaxis in households or medical personnel.

Project type:

The company is looking for a Charité partners to validate and test TXN-C19 in a preclinical study to evaluate the ability of TXN-C19 to decrease morbidity and mortality in COVID-19, using patients' biosamples. In a second stage the product shall be piloted and validated in a clinical population with COVID-19 patients or contact persons.

Estimated Project Duration: 12 Months



Eligible by the IIA



Roy@trioxnano.com



Roy Farfara: +972587127700



Smartriox.com

